Correlation Between Adaptimmune Therapeutics and Immix Biopharma

Can any of the company-specific risk be diversified away by investing in both Adaptimmune Therapeutics and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adaptimmune Therapeutics and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Adaptimmune Therapeutics Plc and Immix Biopharma, you can compare the effects of market volatilities on Adaptimmune Therapeutics and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adaptimmune Therapeutics with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adaptimmune Therapeutics and Immix Biopharma.

Diversification Opportunities for Adaptimmune Therapeutics and Immix Biopharma

0.53

Correlation Coefficient

Adaptimmune Therapeutics  Immix Biopharma

Very weak diversification

The 3 months correlation between Adaptimmune and Immix is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Adaptimmune Therapeutics Plc and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and Adaptimmune Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adaptimmune Therapeutics Plc are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of Adaptimmune Therapeutics i.e., Adaptimmune Therapeutics and Immix Biopharma go up and down completely randomly.

Pair Corralation between Adaptimmune Therapeutics and Immix Biopharma

Given the investment horizon of 90 days Adaptimmune Therapeutics Plc is expected to under-perform the Immix Biopharma. In addition to that, Adaptimmune Therapeutics is 1.48 times more volatile than Immix Biopharma. It trades about -0.22 of its total potential returns per unit of risk. Immix Biopharma is currently generating about -0.11 per unit of volatility. If you would invest  236.00  in Immix Biopharma on December 30, 2024 and sell it today you would lose (66.00) from holding Immix Biopharma or give up 27.97% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Adaptimmune Therapeutics Plc  vs.  Immix Biopharma

Adaptimmune Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Immix Biopharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Immix Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Adaptimmune Therapeutics and Immix Biopharma

The main advantage of trading using opposite Adaptimmune Therapeutics and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adaptimmune Therapeutics position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.

The idea behind Adaptimmune Therapeutics Plc and Immix Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.